Skip to main content
TipRanks
Go Ultimate75% OFF

Annovis Bio (ANVS) AI Stock Analysis

766 Followers
ANVS

Annovis Bio

(NYSE:ANVS)

Select Model
Rating:42Neutral
Price Target:$0.72â–¼(-4.00% Downside)
Action:reiterated
Date:11/15/26

The score is primarily dragged down by weak financial fundamentals typical of a pre-revenue biotech—ongoing losses, sustained cash burn, and especially the reported TTM negative equity—along with a technically weak trend (trading below major moving averages with negative MACD). Corporate-event risk is elevated due to NYSE non-compliance/delisting risk, while valuation signals are not supportive given a negative P/E and no dividend.

Positive Factors
Phase 3 trial oversightTwo consecutive independent safety reviews supporting uninterrupted continuation provide durable evidence that the pivotal trial has cleared important monitoring checkpoints. This can preserve development momentum and reduce the risk of a clinically disruptive safety-driven modification over the next several months.
Negative Factors
Pre-revenue operating modelThe absence of reported revenue means the company currently depends on financing and research progress rather than commercial operations to support its business. Material ongoing losses indicate profitability is not yet visible, leaving future financial strength highly dependent on successful clinical development.

Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%ANVS-77.81%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$32.01M
Dividend Yield
―
Average Volume (3M)
1.75M
Price to Earnings (P/E)
-0.5
Beta (1Y)
2.63
Revenue Growth
―
EPS Growth
-15.00%
Country
US
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for...

Annovis Bio Financial Statement Overview

Summary

Clinical-stage, pre-revenue profile with persistent, material losses and cash burn (TTM EBIT about -$59.1M; TTM operating cash flow about -$55.9M). While the company reports zero debt, the provided data shows a highly concerning TTM negative stockholders’ equity (approximately -$13.23B) and notable equity volatility, which materially weakens the financial risk profile.

Income Statement

9Very Negative

Balance Sheet

12Very Negative

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Mar 2023Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-58.79M-28.85M-22.74M-56.20M-25.33M-14.50M
Net Income-51.72M-28.85M-24.59M-56.20M-25.33M-14.49M
Balance Sheet
Total Assets5.50B21.08M13.93M10.21M36.02M46.00M
Cash, Cash Equivalents and Short-Term Investments2.82B19.53M10.55M5.75M28.38M45.69M
Total Debt000000
Total Liabilities18.74B4.23M4.62M17.96M7.70M1.51M
Stockholders Equity-13.23B16.85M9.31M-7.75M28.32M44.49M
Cash Flow
Free Cash Flow-55.89M-25.62M-21.89M-39.97M-17.31M-9.13M
Operating Cash Flow-55.89M-25.62M-21.89M-39.97M-17.31M-9.13M
Investing Cash Flow000000
Financing Cash Flow43.42M34.60M26.69M17.34M4,61346.74M

Annovis Bio Technical Analysis

Technical Analysis SentimentNegative
Last Price0.75

Price Trends

50DMA1.09Negative
100DMA1.43Negative
200DMA1.80Negative

Market Momentum

MACD-0.08Positive
RSI38.28Neutral
STOCH33.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.09, and below the 200-day MA of 1.80, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.

Annovis Bio Risk Analysis

Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2023 contains an explanatory paragraph relating to our ability to continue as a going concern.Q4, 2023
2.Our recurring operating losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about our ability to continue as a going concern, if we are unable to obtain additional financings.Q4, 2023
3.Disruption, failure or cybersecurity breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations.Q4, 2023

Annovis Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ANVS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DTILDTIL58Neutral$203.37M-5.97-58.09%―6353.01%84.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
COYACOYA43Neutral$70.37M-2.17-71.48%―17.59%-20.34%
ANVSANVS42Neutral$32.01M-0.481.57%――-15.00%
WHWKWHWK40Underperform$177.62M-2.75-55.66%―-100.00%-825.52%
ABOSABOS38Underperform$15.62M-0.14-166.49%――29.92%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%ANVSWHWKDTILGLSIABOSCOYADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ANVS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ANVSAnnovis Bio Inc0.75-2.62-77.74%
WHWKWhitehawk Therapeutics, Inc.3.010.8740.65%
DTILPrecision Biosciences7.282.0639.46%
GLSIGreenwich Lifesciences, Inc.13.765.5266.99%
ABOSAcumen Pharmaceuticals, Inc.0.22-1.44-86.99%
COYACoya Therapeutics, Inc.3.00-3.16-51.30%

Annovis Bio Corporate Events

Private Placements and Financing

Annovis Bio Announces Pricing of Public Offering and Underwriting Agreement

Neutral
Nov 5, 2026

On November 4, 2026, Annovis Bio announced the launch of a public offering, and on November 5, 2026, it entered an underwriting agreement and announced the offering’s pricing. The offering comprised 19 million common shares or pre-funded warrants for...

Regulatory Filings and ComplianceShareholder Meetings

Annovis Bio Files Charter Amendment After Stockholder Approval

Neutral
Nov 4, 2026

On November 3, 2026, Annovis Bio stockholders approved increasing authorized common shares from 70 million to 140 million and ratified an amendment increasing shares authorized under the company’s 2019 Equity Incentive Plan. The company filed the cha...

Regulatory Filings and Compliance

Annovis Bio Clarifies Regulation FD Disclosure in Current Report

Neutral
Nov 4, 2026

Annovis Bio, Inc. said previously disclosed information was incorporated by reference into additional sections of its current report, while clarifying the information was furnished rather than filed under securities-law provisions unless specifically...

Delistings and Listing ChangesRegulatory Filings and Compliance

Annovis Bio Addresses NYSE Non-Compliance Listing Notice

Negative
Oct 30, 2026

On October 29, 2026, Annovis Bio received notice from the New York Stock Exchange that it had fallen out of compliance with continued listing standards because its 30-day average market capitalization and stockholders’ equity were both below the $50...

Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings

Annovis Bio Updates Audit Fee Disclosure for Transparency

Positive
Oct 20, 2026

Annovis Bio disclosed that, due to a typographical error in its proxy statement for the annual meeting of stockholders held on June 17, 2026, it has corrected the previously reported audit fee information. The updated figures show that Ernst & Young...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 15, 2026